Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Merck
Medtronic
Mallinckrodt
Harvard Business School

Last Updated: September 28, 2022

CLINICAL TRIALS PROFILE FOR APD421


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Clinical Trials for APD421

Trial ID Title Status Sponsor Phase Summary
NCT01303978 ↗ Phase II Proof-of-concept Study of APD421 Completed Acacia Pharma Ltd Phase 2 Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin
NCT01510704 ↗ Phase II Dose-ranging Study of APD421 in PONV Completed Acacia Pharma Ltd Phase 2 To assess the efficacy and safety of different doses of APD421 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystectomy (any surgical technique) or "other" elective surgery scheduled to last at least one hour from induction of anaesthesia), requiring at least one overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use for post-operative analgesia.
NCT01991821 ↗ European Phase III Study of APD421 in PONV Completed Acacia Pharma Ltd Phase 3 A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
NCT01991860 ↗ US Phase III Study of APD421 in PONV Completed Acacia Pharma Ltd Phase 3 A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
NCT02337062 ↗ Phase IIIb Study of APD421 in Combination as PONV Prophylaxis Completed Acacia Pharma Ltd Phase 3 A comparison of the efficacy of APD421 and placebo when combined with a standard anti-emetic in the prevention of PONV in patients at high risk of Post-operative Nausea and Vomiting (PONV).
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for APD421

Condition Name

Condition Name for
Intervention Trials
Postoperative Nausea and Vomiting 4
PONV 3
Healthy 1
Post-operative Nausea and Vomiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Postoperative Nausea and Vomiting 8
Vomiting 6
Nausea 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for APD421

Trials by Country

Trials by Country for
Location Trials
United States 16
France 5
Germany 5
United Kingdom 2
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
North Carolina 4
Ohio 3
Florida 3
Alabama 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for APD421

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 5
Phase 2 2
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for APD421

Sponsor Name

Sponsor Name for
Sponsor Trials
Acacia Pharma Ltd 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
McKesson
Boehringer Ingelheim
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.